- Mollie Pearce, star of the UK reality TV show ‘The Traitors’
who was diagnosed with ulcerative colitis (UC), a type of
inflammatory bowel disease (IBD), at the age of 11, partners with
Celltrion to launch a new campaign.
- World IBD Day 2024 sees Celltrion launch the second
installation of the Where’s Crohn’s & Colitis (CC)? campaign,
focused on global inequalities in access to IBD care and
treatment.
- Mollie shares her experiences with UC to highlight the need for
sustainable, equitable care that bridges the gap from diagnosis to
treatment for all.
Celltrion partners with TV star Mollie Pearce to launch the
second installation of the Where’s Crohn’s & Colitis (CC)?
campaign for this year’s World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the
burden of the condition rises globally1. Widening inequalities and
significant variations in access across the globe, and even within
countries, is impacting people’s experience of IBD care and
ultimately their outcomes2.
Through raising awareness of the factors driving these
inequalities and potential solutions, the campaign hopes to
encourage improved access to a timely diagnosis, high quality care
and innovative treatments.
Innovations in treatments, including advances in treatment
administration that enable people to access at-home injectable
treatment (versus hospital-based treatment), allows people to have
an improved quality of life whilst managing their condition3.
The campaign encourages people to look beyond what they would
usually see, to make the invisible condition, visible. In doing so,
users are taken on a journey across borders to explore inequalities
in IBD at a global scale and how these could be overcome.
Reality TV star Mollie Pearce, a contestant on the popular UK
show ‘The Traitors’, partners with Celltrion to launch the
campaign. Mollie was diagnosed with UC when she was 11 years old
and has openly shared her experiences living with the disease as an
advocate for the IBD community, breaking down stigma and inspiring
others to seek the care that works best for them.
Mollie Pearce, media personality and finalist on ‘The
Traitors’, commented: “Living with a condition such as UC comes
with so many challenges - from sometimes not being able to leave
the house to missing out on social occasions with friends. That’s
why I’m so passionate about being an advocate for the IBD community
and helping others to break down barriers and do the things they
never thought were possible once they were diagnosed.
“The Where’s CC? campaign is really close to my heart. I want to
do all I can to ensure everyone is treated as an individual and
gets the care they deserve.”
Mr. Kevin Byoung Seo Choi, Executive VP and head of the
marketing division at Celltrion, said: “It is simply
unacceptable that there are so many barriers in accessing IBD care.
From geographic disparities in access to infusion centers to health
system limitations and education, there is an urgent need to tackle
the root cause of inequalities globally so that all patients can
access potentially life-changing therapies.
“We are committed to tackling inequalities and ensuring a
sustainable future for all IBD patients. The Where’s CC? campaign
is our latest step in making this a reality through raising
awareness and advocating for change.”
The first instalment of the Where’s CC? campaign, launched for
World IBD Day 2023, focused on age-related inequalities in IBD, and
how the challenges that come with the condition can vary at
different stages of life.
Visit www.WhereisCC.com to learn more about the Where’s CC?
campaign and inequalities in access to care and treatment in IBD,
and how these can be overcome to improve IBD outcomes for all.
World IBD Day is an annual awareness campaign led by patient
organisations representing over 50 countries on five continents and
coordinated by the European Federation of Crohn’s and Ulcerative
Colitis Associations (EFCCA)4.
ABOUT INFLAMMATORY BOWEL DISEASE (IBD) IBD is an umbrella
term used to describe conditions including Crohn’s disease and
ulcerative colitis. Collectively, IBD impacts over 10 million
people worldwide with incidence rates rapidly increasing across the
world5.
IBD is a long-term condition and there may be times when the
symptoms are severe, known as a flare-up, and times when there are
no or few symptoms, known as remission. Common symptoms of IBD
include pain, cramping or swelling in the stomach, episodes of
diarrhoea, weight loss and extreme tiredness6. IBD can appear for
the first time at any age, however, diagnosis most commonly takes
place between the ages of 10 and 405.
Treatment for IBD can be transformative for patients’ lives,
reducing the impact of the condition on their lives by minimising
flare-ups and maintaining remission. In recent years, the
increasing availability of new treatments has transformed IBD
patient care.
ABOUT ‘THE TRAITORS’ ‘The Traitors’ is a British reality
TV series involving a group of players who are seemingly focused on
a common goal – the ‘faithfuls’ must eliminate all the ‘traitors’
from the group. Mollie Pearce appeared in Series Two of the
programme, making it to the final where she cast the deciding vote
of the series.
ABOUT CELLTRION Celltrion is a leading biopharmaceutical
company that specializes in research, development and manufacturing
of innovative therapeutics that improve people's lives worldwide.
The company’s portfolio of anti-TNF therapies spans a number of
indications across distinct therapy areas: immunology,
hemato-oncology and ophthalmology. We are dedicated to expanding
patient access to life-changing biologic therapies while generating
healthcare sustainability with meaningful cost savings for patients
worldwide. To learn more, please visit www.celltrion.com/en-us.
FORWARD-LOOKING STATEMENT Certain information set forth
in this press release contains statements related to our future
business and financial performance and future events or
developments involving Celltrion/Celltrion Healthcare that may
constitute forward-looking statements, under pertinent securities
laws.
These statements may be identified by words such as “prepares”,
“hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”,
“is preparing, “once gained”, “could”, “with the aim of”, “may”,
“once identified”, “will”, “working towards”, “is due”, “become
available”, “has potential to”, the negative of these words or such
other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking
statements. Such statements are based on the current expectations
and certain assumptions of Celltrion/Celltrion Healthcare's
management, of which many are beyond its control.
Forward-looking statements are provided to allow potential
investors the opportunity to understand management’s beliefs and
opinions in respect of the future so that they may use such beliefs
and opinions as one factor in evaluating an investment. These
statements are not guarantees of future performance and undue
reliance should not be placed on them.
Such forward-looking statements necessarily involve known and
unknown risks and uncertainties, which may cause actual performance
and financial results in future periods to differ materially from
any projections of future performance or result expressed or
implied by such forward-looking statements.
Although forward-looking statements contained in this
presentation are based upon what management of Celltrion/Celltrion
Healthcare believes are reasonable assumptions, there can be no
assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements.
Celltrion/Celltrion Healthcare undertakes no obligation to update
forward-looking statements if circumstances or management’s
estimates or opinions should change except as required by
applicable securities laws. The reader is cautioned not to place
undue reliance on forward-looking statements.
References
1 The Lancet Gastroenterology & Hepatology. Promoting equity
in inflammatory bowel disease: a global approach to care. Available
at:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00368-0/abstract#back-bib4
[Accessed: May 2024]
2 Journal of Crohn’s and Colitis. P018 Inequalities in
healthcare access, experience and outcomes in adults with
Inflammatory Bowel Disease: A scoping review. Available at:
https://academic.oup.com/ecco-jcc/article/18/Supplement_1/i269/7586146
[Accessed: May 2024]
3 BMC Proceedings. Intravenous versus subcutaneous delivery of
biotherapeutics in IBD: an expert’s and patient’s perspective.
Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654488/#:~:text=Benefits%20of%20the%20subcutaneous%20application%20of%20drugs%20include,are%20able%20to%20administer%20their%20treatments%20at%20home.
[Accessed: May 2024]
4 EFCCA. World IBD Day. Available at: https://worldibdday.org/
[Accessed: May 2024]
5 EFCCA. What is IBD? Available at:
https://efcca.org/content/what-ibd [Accessed: May 2024]
6 NHS. Inflammatory bowel disease. Available at:
https://www.nhs.uk/conditions/inflammatory-bowel-disease/
[Accessed: May 2024]
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240517193492/en/
Holly Barber hbarber@hanovercomms.com +44 (0) 7759 301620